Los Angeles Capital Management
VNDA icon

Los Angeles Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Los Angeles Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$207K Buy
29,906
+29,425
+6,117% +$227K ﹤0.01% 1135
2025
Q4 		$2.08K Buy
+481
New +$2.65K ﹤0.01% 2426
2025
Q3 		– Sell
-44,696
Closed -$211K – 1549
2025
Q2 		$211K Buy
44,696
+6,765
+18% +$29.6K ﹤0.01% 1181
2025
Q1 		$174K Sell
37,931
-194,150
-84% -$905K ﹤0.01% 1040
2024
Q4 		$1.11M Sell
232,081
-44,800
-16% -$215K ﹤0.01% 584
2024
Q3 		$1.3M Sell
276,881
-48,080
-15% -$258K 0.01% 559
2024
Q2 		$1.84M Sell
324,961
-106,263
-25% -$549K 0.01% 476
2024
Q1 		$1.77M Buy
431,224
+64,670
+18% +$259K 0.01% 527
2023
Q4 		$1.55M Sell
366,554
-99,400
-21% -$401K 0.01% 537
2023
Q3 		$2.01M Buy
465,954
+138,284
+42% +$768K 0.01% 450
2023
Q2 		$2.16M Buy
327,670
+89,545
+38% +$574K 0.01% 475
2023
Q1 		$1.62M Buy
238,125
+169,768
+248% +$1.19M 0.01% 547
2022
Q4 		$505K Sell
68,357
-1,519
-2% -$14.8K ﹤0.01% 904
2022
Q3 		$690K Sell
69,876
-2,000
-3% -$21.1K ﹤0.01% 826
2022
Q2 		$783K Sell
71,876
-10,519
-13% -$109K ﹤0.01% 811
2022
Q1 		$932K Hold
82,395
– – ﹤0.01% 792
2021
Q4 		$1.29M Buy
82,395
+25
+0% +$436 ﹤0.01% 633
2021
Q3 		$1.41M Buy
82,370
+28,421
+53% +$498K 0.01% 627
2021
Q2 		$1.16M Sell
53,949
-6,730
-11% -$120K 0.01% 790
2021
Q1 		$911K Sell
60,679
-30,799
-34% -$499K ﹤0.01% 935
2020
Q4 		$1.2M Sell
91,478
-1,225
-1% -$14.7K 0.01% 857
2020
Q3 		$896K Sell
92,703
-57,661
-38% -$616K ﹤0.01% 862
2020
Q2 		$1.72M Sell
150,364
-61,268
-29% -$694K 0.01% 652
2020
Q1 		$2.19M Sell
211,632
-62,642
-23% -$777K 0.01% 515
2019
Q4 		$4.5M Buy
274,274
+40,860
+18% +$618K 0.02% 435
2019
Q3 		$3.1M Buy
233,414
+197,952
+558% +$2.76M 0.02% 519
2019
Q2 		$500K Sell
35,462
-1,740
-5% -$27.7K ﹤0.01% 1040
2019
Q1 		$685K Sell
37,202
-45,150
-55% -$1.03M ﹤0.01% 988
2018
Q4 		$2.15M Sell
82,352
-11,990
-13% -$282K 0.01% 535
2018
Q3 		$2.17M Buy
94,342
+56,620
+150% +$1.16M 0.01% 648
2018
Q2 		$719K Hold
37,722
– – ﹤0.01% 1029
2018
Q1 		$636K Buy
37,722
+125
+0.3% +$2.09K ﹤0.01% 959
2017
Q4 		$571K Buy
37,597
+22,105
+143% +$328K ﹤0.01% 1013
2017
Q3 		$277K Buy
+15,492
New +$259K ﹤0.01% 1171
2013
Q3 		– Sell
-42,058
Closed -$340K – 1371
2013
Q2 		$340K Buy
+42,058
New +$283K ﹤0.01% 1035

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's VNDA Position: Q1 2026 in Review

Los Angeles Capital Management increased its Vanda Pharmaceuticals (VNDA) stake by 6,117% in Q1 2026, buying an estimated $227K and bringing the position to 29,906 shares worth $207K. The position accounts for ﹤0.01% of the portfolio, ranked #1135.

Los Angeles Capital Management first reported a position in VNDA in Q2 2013 and has held it in 35 quarters since. The position peaked at $4.5M in Q4 2019. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Los Angeles Capital Management held 29,906 shares of Vanda Pharmaceuticals worth $207K as of Q1 2026.
  • Los Angeles Capital Management bought 29,425 Vanda Pharmaceuticals shares in Q1 2026, an estimated $227K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1135 holding.
  • Los Angeles Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Los Angeles Capital Management's Vanda Pharmaceuticals position peaked at $4.5M in Q4 2019.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.